Previously published studies on the biodistribution and kinetics of 68Ga-PSMA-11 in prostate cancer patients reported increasing SUV in tumor lesions from early to late imaging and rapid blood clearance of 68Ga-PSMA-11 [10–12]. This evidence concerns the gene FOLH1 and prostate carcinoma.